Time ID# Titile First Author  Tuesday, May 22 AM 9:00-10:00 Virology and molecular Biology (I) AM:9:00-9:15 30 HTLV-I bZIP Factor (HBZ) Acts at Different Levels to Control the Transcriptional Activity of the Different Members of the Jun Family Patrick Hivin AM:9:15-9:30 160 HTLV-I bZIP Factor Gene and Oncogenesis by HTLV-I Masao Matsuoka AM:9:30-9:45 102 The HBZ as a Cofactor in the Transcriptional Upregulation of the Human Telomerase Reverse Transcriptase Gene Anne-Sophie Kuhlmann AM:9:45-10:00 250 A centrosomal target of HTLV-I Tax on the road to genome instability Dong-Yan Jin AM 10:20-11:20 Virology and Molecular Biology (II) AM:10:20-10:35 91 The HTLV-I Tax Oncoprotein Interferes with DNA Double Strand Break Recognition and Repair Chandtip Chandhasin AM:10:35-10:50 112 Activation of NF-kB2/p100 by Human T-cell Leukemia Virus Type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is Crucial for Interleukin-2 Independent Growth Transformation of a T Cell Line. Masaya Higuchi AM:10:50-11:05 311 Possible involvement of TORC2 in the transcriptional suppression of HTLV-1 in vivo ShiWen Jiang AM:11:05-11:20 73 HTLV-2 Rex Carboxy Terminus Functions as a Novel Inhibitory Domain to Regulate Rex Activity and Viral Replication in vitro and in vivo Li Xie AM 11:30-12:45 Clinical Hematology (I)Pathophysiology and Immunolopathology, etc AM:11:30-11:45 307 Gene expression profiling of ATL patients: identification of signaling pathways which contribute to ATL Cynthia A. Pise-Masison AM:11:45-PM:12:00 273 Molecular allelo-karyotyping of adult T-cell leukemia using high SNP genotyping microarrys Satsuki Muto PM:12:00-12:15 170 Upregulation of Oncogenic MicroRNAs in HTLV-1 Transformed Lymphocytes and ATL Cells Klemens Pichler PM:12:15-12:30 93 Antibody as a Novel Beacon for Progression in ATL Patients Yasuko Sagara PM:12:30-12:45 42 Immunological Response and Disease Expression in HTLV-1 Edgar M Carvalho PM 2:00-3:30 Clinical Hematology (II) therapy (I) chemotherapy PM:2:00-2:15 225 Clinical Trials for the Treatment of adult T-cell leukemia/lymphoma (ATLL) by the Japan Clinical Oncology Group (JCOG) Kunihiro Tsukasaki PM:2:15-2:30 208 A long-term study of prognosis in indolent types of Adult T-cell leukemia/ lymphoma (ATLL). Yumi Takasaki PM:2:30-2:45 269 A worldwide meta-analysis on the use of zidovudine and interferon-alpha for the treatment of adult T-cell leukemia/lymphoma Olivier Hermine PM:2:45-3:00 106 Chemoantiretroviral Therapy for Adult T Cell Leukemia Lymphoma Lee Ratner PM:3:00-3:15 231 IRF-4 and Interferon Resistance in Adult T-cell Leukemia Juan Carlos Ramos PM:3:15-3:30 276 A Phase I Trial of Siplizumab in CD2 Positive Lymphoproliferative Disease. Deirdre O'Mahony PM 3:45-4:45 Clinical Hematology (III): Therapy (II) HSCT PM:3:45-4:00 108 Comparable Outcome of Reduced-Intensity Conditioning with or without Antithymocyte Globulin in Allogeneic Stem Cell Transplantation for Adult T-cell Leukemia:The Results of Two Prospective Studies Naokuni Uike PM:4:00-4:15 221 Reduced-Intensity Stem Cell Transplantation is Relatively Safe and Effective in Patients with Adult T-Cell Leukemia/Lymphoma (ATLL) Ryuji Tanosaki PM:4:15-4:30 77 Rare Minimal Residual Disease (MRD) and Small Amount of Carrier Lymphocytes in Adult T Cell Leukemia/Lymphoma (ATLL) Patients after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Reishi Yamasaki PM:4:30-4:45 242 Positive conversion of Tax-specific CTL response in ATL patients after hematopoietic stem cell transplantation Nanae Harashima       Thursday, May 24 AM 8:30-9:30 Epidemiology and Phylogenesis (I) AM:8:30-8:45 287 Neurological evaluation of HTLV-1-infected and uninfected children in Peru Antonis Mirsaliotis AM:8:45-9:00 226 Anti-HTLV-1 Ab prevalence in Japanese blood donors Masahiro Satake AM:9:00-9:15 23 Nationwide Cohort Study of HTLV-1 Carriers in Japan: Joint Study on Predisposing Factors of ATL Development (JSPFAD) Kazunari Yamaguchi AM:9:15-9:30 59 Prospective Analysis of Neurological Abnormalities in a Cohort of HTLV-I and HTLV-II Infection. Zhanna Kaidarova AM 9:40-10:40 Laboratory Diagnosis and Testing AM:9:40-9:55 322 Measurement of the provirus copy number of JSPFAD samples by a multiplex real-time PCR system Shigemi Aizawa AM:9:55-10:10 70 Multiplex Real-time PCR for Simultaneous Detection Genotyping and Proviral Load Determination of Human T-lymphotropic Virus types 1 to 3. Sonia Van Dooren AM:10:10-10:25 29 Development and Performance Evaluation of a Serological Assay for Detection of HTLV-I and HTLV-II Infections Xiaoxing Qiu AM:10:25-10:40 176 Agreement Between Three Enzyme Immunoassays (EIA) for the Diagnosis of HTLV Infection in a High Prevalence Setting in Lima Peru Kristien Verdonck AM 11:00-12:00 Epidemiology and Phylogenesis (II) AM:11:00-11:15 187 Complete Genome Analysis of the Novel Human T-lymphotropic Virus Type 4 Reveals an Ancient Ancestor and Unique Molecular Features William M Switzer AM:11:15-11:30 264 Identification and Complete Sequence Analysis of a New HTLV-3 Strain from South Cameroon. Sara Calattini AM:11:30-11:45 245 Anthropo-genetic approach on Mongoloids HTLV Dispersal in Pan-Pacific Regions Kazuo Tajima AM:11:45-PM:12:00 100 A Major Susceptibility Locus for HTLV-1 Infection in Childhood Maps to Chromosome 6q27 Sabine Plancoulaine PM 1:30-3:00 Immunology PM:1:30-1:45 129 Human Blood Brain Barrier Disruption by HTLV-infected T Lymphocytes: Model for Endothelial Tight-Junctions Disorganization during HAM/TSP Philippe Afonso PM:1:45-2:00 167 Induction of the Co-stimulatory Receptor 4-1BB in HTLV-1 Transformed T Cells likely Augments Survival and Growth Klemens Pichler PM:2:00-2:15 124 Regulatory T-cell Function of Adult T-Cell Leukemia/Lymphoma Cells Hiroki Yano PM:2:15-2:30 39 Control of CTL Response to HTLV-1 Virus by Regulatory T Cells in Asymptomatic Carriers HAM/TSP Patients and ATL Patients Frederic Toulza PM:2:30-2:45 228 HTLV-I proviral load at equilibrium in orally infected rats can be reduced by restoration of HTLV-I-specific T-cell response following re-immunization Kazuya Komori PM:2:45-3:00 42 Immunological Response and Disease Expression in HTLV-1 Edgar M Carvalho PM 3:15-4:15 Clinical Neurology PM:3:15-3:30 49 Impaired Maturation and Function of HTLV-1 Specific CTLs in HAM/TSP. Mineki Saito PM:3:15-3:30 235 ONE YEAR FOLLOW UP STUDY OF PROVIRAL LOADS AND TAX GENE EXPRESSION IN 19 HAM/TSP PATIENTS TREATED WITH VALPROATE Agnès Lezin PM:3:30-3:45 262 Bystander damage of the central nervous system by HTLV-I-specific CTL with target cell infiltration in HAM/TSP Eiji Matsuura PM:3:45-4:00 144 Study on the Genetic Polymorphism of the HTLV-1 U3-LTR Region Isolated from Asymptomatic and Symptomatic (TSP/HAM) Infected Individuals from Salvador Bahia Brazil. Sérgio A Pereira PM:4:00-4:15 265 Therapeutic potentials of allicin and its derivative against HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Yoshihiro Nishiura       Friday, May 25 AM 8:30-10:15 Cirology and Molecular Biology (III) AM:8:30-8:45 135 Construction and Characterization of a Full Length Infectious Simian T-cell Lymphotropic Virus Type-3 Molecular Clone Sebastien Chevalier AM:8:45-9:00 300 HTLV-1 INFECTION LEADS TO CELL CYCLE ARREST/SENESCENCE THAT CAN BE PREVENTED BY A LOSS OF CDK INHIBITORS P21CIP1/WAF1 AND P27KIP1. Meihong Liu AM:9:00-9:15 113 Dysregulation of Mitotic Checkpoint Proteins Chfr and Aurora A in HTLV-I-infected T-cells Mariko Tomita AM:9:15-9:30 55 Enhancement of LFA-1-Mediated T-Cell Adhesion and Viral Transmission by Human T-Lymphotropic Virus Type 1 p12 Seung-jae Kim AM:9:30-9:45 278 Anti-viral Strategies Targeting the Fusion-active Structures of HTLV-1 Envelope Antonis Mirsaliotis AM:9:45-10:00 142 HTLV-1 Tax Disrupts the Cellular DNA Damage Response via Binding and Sequestration of Active DNA-PK Sarah S Durkin AM:10:00-10:15 26 Preferential Integration of HTLV-1 in Transcriptionally Active Regions in vivo Increases HTLV-1 Transcription and the Risk of the Inflammatory Disease HAM/TSP Kiran N Meekings AM 10:30-11:30 Virology and Molecular Biology (IIIV) AM:10:30-10:45 306 Tax recruits DEK on the hTERT promoter. Franck Mortreux AM:10:45-11:00 198 Identification of Tax Binding Sites Within the Genome of an HTLV-1-infected T-cell Line Nicholas J Polakowski AM:11:00-11:15   Inhibition of p53 function by the Tax oncoprotein of HTLV-1 requires Tax ubiquitination but not NF-kappaB activity Isabelle Lamsoul AM:11:15-11:30 303 Tax Promotes CREB Phosphorylation, Increasing the Level of a Critical Mediator of Tax Function Young-Mi Kim AM 11:40-12:40 Animal Models and Translational Research (I) AM:11:40-11:55 67 In vivo Model for Primary HTLV-I Infection of Human Lymphocytes Paola Miyazato AM:11:55-PM:12:10 48 Proliferation of HTLV-Infected PBMC from Asymptomatic Carriers in NOD/SCID/³Null (NOG) Mice Akihiko Okayama PM:12:10-12:25 117 Cell Dynamics and Immune Response to BLV Infection: a Unifying Model Arnaud Florins PM:12:25-12:40 52 Immune Suppression with Cyclosporine Increases HTLV-1 Replication During the Early Phase of Infection in the Rabbit Model Andrew J Phipps PM 2:00-3:45 Animal Modelas and Translational Research (II) PM:2:00-2:15 41 Development T cell Leukemia/Lymphoma and Arthropathy in Transgenic Mice Carrying Human T-cell Leukemia Virus Type I tax Gene Takeo Ohsugi PM:2:15-2:30 344 T Lymphocyte Proliferation and Disease Induced by HTLV-1 Infection of Humanized NOD/SCID Mice Prabal Banerjee PM:2:30-2:45 298 Bioluminescence Imaging of Spontaneous Lymphomagenesis In-Vivo Daniel Rauch PM:2:45-3:00 224 Adult T cell leukemia/lymphoma(ATLL): Exploitation of transgenic mouse model to understand disease pathogenesis and for the development of rational therapeutics. Akira Kawaguchi PM:3:00-3:15 268 Design of new targeted therapies for HTLV-I associated adult T-cell leukemia/lymphoma using SCID mice injected with lymphoma spleen cells from mice transgenic for the Tax gene of HTLV- I Hiba El Hajj PM:3:15-3:30 56 Efficacy Studies of Bortezomib (PS-341) and 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) in a Preclinical Mouse Model of Adult T-cell Lymphoma Bevin Zimmerman PM:3:30-3:45 239 A water-soluble Hsp90 inhibitor 17-DMAG suppresses Tax-mediated oncogenic signaling both in vitro and in vivo Hidekatsu Iha